h as 'letter re claim,' analysis of claim,' or report in anticipation of litigation' . . . will be insufficient." Id. (citing Abbott Laboratories v. Alpha Therapeutic Corp., 2000 U.S. Dist. LEXIS 20834, 2000 WL 1863543 fl III. Dec. 14, 2000). 4. In this Log, there is no identification whatsoever of the type of docume

valuation of and challenges to the privileges asserted therein. TIG Ins. Cap. v. Johnson, 799 So. 2d 339 (Fla. 4th DCA 2001); Abbott Laboratories v. Alpha Therapeutic Corp., No. 97-C-1292, 2000 WL 1863543 (N.D. III. Dec. 14, 2000). Moreover, none of the general references for which Edwards would have Epstein sanctioned

valuation of and challenges to the privileges asserted therein. TIG Ins. Cap. v. Johnson, 799 So. 2d 339 (Fla. 4th DCA 2001); Abbott Laboratories v. Alpha Therapeutic Corp., No. 97-C-1292, 2000 WL 1863543 (N.D. III. Dec. 14, 2000). Had the Court issued the expansive prohibition sought by Edwards, it would have effectiv